ELISA Assay Validation: Key Parameters and Protocols

ELISA assay validation is the process of demonstrating through documented evidence that an enzyme-linked immunosorbent assay performs reliably for its intended purpose. For laboratory students, technicians, researchers, and diagnostic professionals, validation provides the confidence that results generated by the assay are accurate, precise, and reproducible across runs, operators, and days. This article covers the core validation parameters, practical protocols for assessing each parameter, acceptance criteria, documentation requirements, and common pitfalls encountered during validation studies.

At a Glance: Core Validation Parameters and Acceptance Criteria

The table below summarizes the primary validation parameters, what each measures, and typical acceptance criteria reported in published validation studies. These values serve as starting points for establishing your own validation protocol, not as universal requirements.

Understanding ELISA Validation and Its Purpose

Validation answers a straightforward question: does this assay produce trustworthy results for the samples and conditions in which it will be used? The process generates documented evidence that the method performs consistently and measures what it claims to measure. Without validation, results from an ELISA cannot be interpreted with confidence, particularly when those results inform clinical decisions, regulatory submissions, or food safety assessments.

The World Health Organization Laboratory Quality Management System Handbook emphasizes that all examination procedures must be validated before use in a diagnostic laboratory. This requirement applies to commercial kits and in-house assays alike. Commercial kits arrive with manufacturer claims, but the laboratory must verify that the kit performs as expected in its specific setting, with its equipment, operators, and sample types.

Validation also serves practical purposes beyond regulatory compliance. A validated assay reduces the risk of reporting incorrect results that could lead to misdiagnosis, inappropriate treatment decisions, or faulty research conclusions. For veterinary applications, an unvalidated ELISA could produce false negatives that allow diseased animals to remain in a herd, or false positives that lead to unnecessary culling. The stakes of validation failures are concrete and measurable.

Core Validation Parameters and Their Assessment

Accuracy and Recovery

Accuracy describes how close a measured value comes to the true concentration of the analyte in a sample. In practice, accuracy is most often assessed through spike recovery experiments. A known quantity of the target analyte is added to a sample matrix, the sample is tested, and the measured concentration is compared to the expected concentration.

A simplified validation study for a microcystin ELISA kit reported spike recovery within 70% to 130% for spiked and proficiency samples. A progranulin assay validation reported spike recovery of 96%. An aflatoxin kit validation in spices reported recovery rates ranging from 95.09% to 110.29%. These figures illustrate that acceptable recovery varies by assay type, matrix complexity, and the intended use of the results.

For your validation protocol, prepare samples at multiple concentration levels spanning the assay working range. Include at least three levels: low, medium, and high relative to the expected range of patient or field samples. Spike each level in replicate, test the samples, and calculate percent recovery using this formula:

Percent recovery equals measured concentration divided by expected concentration, multiplied by 100.

Document the recovery at each level and compare against your pre-defined acceptance criteria. If recovery falls outside the acceptable range, investigate potential causes including matrix interference, incomplete extraction, or degradation of the spiked analyte.

Precision: Repeatability, Intermediate Precision, and Reproducibility

Precision measures the agreement between replicate measurements of the same sample. It is expressed as the coefficient of variation, which is the standard deviation divided by the mean, expressed as a percentage. Lower coefficients of variation indicate better precision.

Precision is assessed at three levels. Repeatability, also called intra-assay precision, measures variation within a single assay run. Intermediate precision measures variation between runs on different days, with different operators, or with different reagent lots. Reproducibility measures variation between laboratories or across extended time periods.

Published validation studies report a range of precision values. The microcystin kit validation reported intra-assay variability below 11%, inter-assay variability below 15%, and reproducibility below 21%. A progranulin assay reported coefficients of variation below 7% for precision and repeatability. An in-house porcine circovirus type 2d ELISA reported reproducibility with coefficients of variation below 5%. An anti-Saccharomyces cerevisiae antibody assay reported repeatability between 7.93% and 10.61% and intermediate precision between 7.93% and 11.43%. The aflatoxin kit validation reported repeatability of 3.14%, intermediate precision of 6.82%, and reproducibility of 13.96%.

To assess precision in your laboratory, test at least three concentration levels across the working range. For repeatability, run multiple replicates of each level within a single plate. For intermediate precision, repeat the testing on at least three separate days, ideally with different operators. Calculate the coefficient of variation for each level and each precision component.

Sensitivity: Limit of Detection and Limit of Quantification

Sensitivity describes the ability of the assay to detect low concentrations of the analyte. Two related parameters are commonly reported. The limit of detection is the lowest concentration that can be reliably distinguished from a blank sample. The lower limit of quantification is the lowest concentration that can be measured with acceptable accuracy and precision.

The microcystin validation reported a limit of detection of 0.002 μg/L and a lower limit of quantification of 0.05 μg/L. The aflatoxin kit validation reported detection and quantification limits of 0.15 mg/kg and 0.50 mg/kg respectively. A progranulin assay reported a measurement range of 6.25 to 400 μg/L.

Several approaches exist for determining the limit of detection. One common method involves testing multiple replicates of a blank sample, calculating the mean and standard deviation of the signal, and defining the limit of detection as the mean plus two or three standard deviations. Another approach uses the standard curve to calculate the concentration corresponding to the signal threshold.

The choice of method for determining sensitivity should be documented in your validation protocol. The limit of detection and lower limit of quantification must be appropriate for the concentrations expected in your samples. If clinical or field samples contain analyte concentrations near the limit of detection, results should be interpreted with caution and confirmed with a more sensitive method if available.

Specificity and Cross-Reactivity

Specificity measures the ability of the assay to detect only the target analyte without interference from related compounds or matrix components. Cross-reactivity occurs when antibodies in the assay bind to molecules other than the intended target.

The microcystin validation assessed specificity using seven microcystin analogues and three amino acids, finding cross-reactivity below 30%. The porcine circovirus type 2d ELISA tested specificity against PCV2a, PCV2b, and porcine reproductive and respiratory syndrome virus, finding minimal cross-reactivity below 7%. The anti-Saccharomyces cerevisiae antibody assay demonstrated specificity through background noise suppression, achieving 100% inhibition as evidence of assay specificity.

To assess specificity, test structurally related compounds, potentially interfering substances, and matrix components at relevant concentrations. Document the cross-reactivity of each compound tested. For diagnostic assays, specificity also relates to the ability to correctly identify negative samples, which is assessed through receiver operating characteristic analysis.

Linearity and Dilutional Parallelism

Linearity describes the relationship between measured and expected concentrations across the assay working range. Dilutional parallelism assesses whether high-concentration samples can be diluted into the working range without introducing bias.

The microcystin validation reported a coefficient of determination above 0.99 for the standard curve. The porcine circovirus type 2d ELISA reported linearity with a coefficient of determination of 0.9890. The progranulin assay reported dilution linearity ranging from 1:50 to 1:200.

To assess linearity, prepare serial dilutions of a high-concentration sample and test each dilution. Plot measured concentration against expected concentration and calculate the coefficient of determination. The slope of the regression line should be close to 1.0, indicating that measured values increase proportionally with expected values.

Dilutional parallelism is particularly important when samples may contain analyte concentrations above the upper limit of the working range. The microcystin validation recommended diluting samples to the working range when concentrations exceeded 5 μg/L. Your validation protocol should define the maximum dilution factor that maintains accuracy and precision.

Establishing Cut-Off Values

For qualitative and semi-quantitative assays, establishing the cut-off value that distinguishes positive from negative results is a critical validation step. Several statistical approaches are available, and the choice of method affects assay performance.

A validation study for SARS-CoV-2 antibody ELISAs compared multiple methods for determining cut-off optical density values, including mean plus two standard deviations, mean plus three standard deviations, four-fold above blanks, bootstrapping, and receiver operating characteristic analysis. The study selected receiver operating characteristic analysis as the best method, achieving spike-directed sensitivity of 95.33% and specificity of 94.15%.

A bovine tuberculosis ELISA validation used receiver operating characteristic analysis to establish a corrected optical density cut-off of 0.3853, achieving specificity of 95.95% and a positive predictive value of 83.72%. A diphtheria antitoxin study used receiver operating characteristic analysis to identify ELISA cut-off values corresponding to toxin neutralization test cut-offs of 0.01 and 0.1 IU/mL.

For your assay, consider the clinical or field context when selecting a cut-off method. Receiver operating characteristic analysis requires a well-characterized panel of known positive and negative samples. When such a panel is unavailable, alternative methods such as mean plus standard deviations of negative samples may be used, but the limitations of these approaches should be documented.

Practical Validation Workflow

Step 1: Define the Intended Use and Validation Scope

Before beginning validation experiments, document the intended use of the assay. Specify the analyte, sample types, matrix, concentration range of interest, and the decisions that will be made based on results. The validation scope should reflect the intended use. An assay used for clinical diagnosis requires more extensive validation than an assay used for preliminary research screening.

The World Health Organization Laboratory Quality Management System Handbook provides a framework for matching validation rigor to the intended use of the procedure. Consider whether the assay will be used for qualitative screening, quantitative measurement, or confirmation of results from another method.

Step 2: Review Existing Information and Manufacturer Claims

For commercial kits, review the manufacturer documentation including the package insert, certificates of analysis, and any published validation data. This information provides a starting point for your verification studies. For in-house assays, review the development history, optimization experiments, and any prior validation data.

The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides detailed guidance on assay development and validation for research applications. This resource is particularly useful for in-house assay developers.

Step 3: Prepare Validation Materials

Assemble the materials needed for validation including reference standards, quality control samples, matrix blanks, and panels of known positive and negative samples. Reference standards should be traceable to a recognized reference material when available. Quality control samples should be prepared at concentrations spanning the working range.

For diagnostic validation, a panel of well-characterized clinical or field samples is essential. The bovine tuberculosis ELISA validation used samples from cattle in Mycobacterium bovis-free herds as negative controls and confirmed infected cattle as positive controls. The progranulin assay validation used plasma from confirmed GRN mutation carriers and cognitively healthy individuals.

Step 4: Execute Validation Experiments

Run the validation experiments according to your protocol. Include appropriate controls on every plate. Record all raw data, including optical density readings, standard curve values, and quality control results. Maintain a validation notebook or electronic record that documents all experimental conditions.

The SARS-CoV-2 antibody validation study assessed assay uniformity, accuracy, inter-assay and inter-operator precision, and parallelism. The progranulin validation assessed precision, selectivity, measurement range, dilution linearity, interferences, and sample stability. Your validation should cover the parameters relevant to your assay and intended use.

Step 5: Analyze Data and Compare Against Acceptance Criteria

Calculate each validation parameter and compare the results against your pre-defined acceptance criteria. Document any parameters that fail to meet acceptance criteria and investigate the causes. Some failures may be correctable through protocol optimization, while others may indicate fundamental assay limitations.

Step 6: Write the Validation Report

The validation report documents the entire validation process including the protocol, results, data analysis, and conclusions. The report should be detailed enough that another laboratory could reproduce the validation. Include the following sections:

• Assay description and intended use
• Validation protocol and acceptance criteria
• Results for each validation parameter
• Data tables and statistical analysis
• Conclusions about assay suitability
• Limitations and conditions of use
• Approval signatures and dates

Records and Measurements to Maintain

Validation generates substantial documentation that must be maintained for regulatory compliance and quality assurance. The World Health Organization Laboratory Quality Management System Handbook emphasizes the importance of documentation in laboratory quality systems.

Maintain the following records:

• Validation protocol and approval documents
• Raw data including plate reader output files
• Standard curve data for each run
• Quality control results
• Operator training records
• Equipment calibration and maintenance records
• Reagent lot numbers and expiration dates
• Sample inventory and handling logs
• Validation report and approval signatures

For diagnostic laboratories, these records may be subject to inspection by regulatory authorities. Records should be retained according to applicable regulations and laboratory policies.

Common Failure Patterns and Troubleshooting

Poor Precision

High coefficients of variation often result from inconsistent pipetting, uneven plate washing, temperature variation across the plate, or timing inconsistencies between wells. The aflatoxin kit validation identified a critical point of the method as incubation for 30 minutes at room temperature, indicating that timing control is essential for reproducibility.

To troubleshoot precision failures, examine your pipetting technique, verify that the plate washer is functioning correctly, and monitor temperature stability during incubation steps. Consider using multichannel pipettes and automated washers to reduce operator variability.

Poor Accuracy

Recovery values outside the acceptable range may indicate matrix interference, incomplete extraction, or degradation of the analyte. The progranulin validation found that hemolysis did not interfere with progranulin levels and that the analyte was resistant to freeze-thaw cycles and storage at different temperatures. Not all analytes share these properties, so stability testing is essential.

If recovery is consistently low, investigate whether the spiked analyte is binding to container surfaces, being degraded by matrix enzymes, or being masked by matrix components. If recovery is consistently high, investigate whether the matrix contains endogenous analyte or cross-reacting substances.

Poor Linearity

Non-linear dilution responses may indicate that the assay is operating outside its working range, that matrix effects change with dilution, or that the standard curve is not appropriate for the sample matrix. The microcystin validation recommended diluting samples to the working range when concentrations exceeded 5 μg/L, illustrating the importance of understanding the assay range.

High Background Signal

Elevated background signal reduces assay sensitivity and may indicate inadequate blocking, excessive conjugate concentration, or contamination. Review your blocking conditions, optimize conjugate concentration, and verify that washing steps are adequate.

Cut-Off Instability

If the cut-off value varies between runs, investigate whether the negative control population is stable, whether plate-to-plate variation is excessive, or whether the statistical method for cut-off determination is appropriate. The SARS-CoV-2 validation study compared multiple statistical methods and selected receiver operating characteristic analysis based on superior performance.

Sample Stability and Pre-Analytical Considerations

Sample stability is a validation parameter that is often overlooked but has significant practical implications. The progranulin validation assessed sample stability under various conditions including freeze-thaw cycles and storage at different temperatures, finding that progranulin levels were resistant to these conditions. Not all analytes share this stability, so each assay requires its own stability assessment.

The diphtheria antitoxin validation compared paired serum and dried blood spot samples, finding that ELISA results on dried blood spots showed good diagnostic performance compared to the toxin neutralization test. This finding has practical implications for field studies where cold chain storage is unavailable.

For your validation, assess the stability of the analyte in the sample matrix under the conditions that samples will experience during collection, transport, storage, and testing. Document the maximum storage time and temperature conditions that maintain acceptable analyte recovery.

Matrix Effects and Interference Testing

Matrix effects occur when components of the sample matrix interfere with the assay, producing inaccurate results. The progranulin validation assessed interferences and found that hemolysis did not interfere with progranulin levels. The SARS-CoV-2 validation found that serum and plasma optical density values were highly correlated with a correlation coefficient of 0.93.

Interference testing should include common matrix components such as hemoglobin, bilirubin, lipids, and medications that may be present in patient samples. For veterinary assays, test the relevant species-specific matrix components. The porcine circovirus type 2d ELISA validation included cross-species comparison between guinea pig and porcine sera, finding a positive correlation and acceptable agreement.

If matrix effects are identified, options include sample dilution, matrix-matched standards, or alternative sample preparation methods. The microcystin validation recommended dilution to the working range for samples exceeding 5 μg/L, which also serves to reduce matrix effects.

Assay Optimization Before Validation

Validation should be performed on an optimized assay. The porcine circovirus type 2d ELISA validation included optimization of antigen coating, blocking agent, and substrate incubation before analytical performance was evaluated. The optimal performance was achieved using 105 genomic copies per mL of antigen coating and 5% bovine serum albumin as the blocking agent.

Optimization experiments should be documented separately from validation experiments. Optimization establishes the assay conditions, while validation demonstrates that those conditions produce reliable results. Combining optimization and validation data can obscure the distinction between assay development and assay verification.

Regulatory Context and Guidelines

Several regulatory and guidance documents inform ELISA validation practices. The U.S. Food and Drug Administration Bioanalytical Method Validation Guidance provides recommendations for validating bioanalytical methods used in drug development and regulatory submissions. This guidance covers accuracy, precision, selectivity, sensitivity, reproducibility, and stability.

The World Health Organization Laboratory Quality Management System Handbook provides guidance for diagnostic laboratories implementing quality systems, including requirements for method validation. The World Health Organization Laboratory Biosafety Manual provides guidance on safe handling of biological materials, which is relevant when validating assays that use infectious agents or clinical samples.

The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides detailed technical guidance for assay development and validation in research settings. This resource covers assay design, optimization, validation, and troubleshooting.

For veterinary diagnostic assays, the World Organization for Animal Health establishes validation requirements. The bovine tuberculosis ELISA validation reported that estimated validation parameters were within the established requirements of the World Organization for Animal Health.

Risk-Based Validation Approaches

Not all assays require the same level of validation rigor. A risk-based approach tailors validation activities to the intended use of the assay and the consequences of incorrect results. The immunogenicity assessment for vidutolimod describes a risk-driven approach where a thorough immunogenicity risk assessment led to a simplified one-tiered testing strategy. This example illustrates that validation design should be driven by the specific characteristics and risks of the assay.

For research assays used for preliminary screening, a reduced validation may be appropriate. For diagnostic assays that inform clinical decisions, full validation with well-characterized sample panels is essential. The Italian Societies of Neurology and Clinical Biochemistry position paper on blood-based biomarkers for Alzheimer's disease emphasizes that clinical implementation requires harmonized analytical validation, standardized procedures, and clear guidance on appropriate use and interpretation.

Point-of-Care and Decentralized Testing Considerations

The expansion of point-of-care diagnostics introduces additional validation considerations. A review of point-of-care infectious disease diagnostics emphasizes that rigorous validation, including analytical accuracy, clinical performance in intended-use settings, and usability testing, remains central to ensuring reliability in decentralized environments.

For point-of-care ELISA-based assays, validation must consider the operators who will perform the test, the environmental conditions where testing occurs, and the stability of reagents under field conditions. The diphtheria antitoxin validation using dried blood spots illustrates how validation can support testing in resource-limited settings where traditional sample collection and storage are not feasible.

Professional Escalation Criteria

Validation results that fall outside acceptance criteria require professional judgment about whether the assay is suitable for its intended use. Escalate the following situations to a laboratory supervisor, quality manager, or method validation committee:

• Consistent failure to meet acceptance criteria for accuracy or precision
• Evidence of significant matrix effects that cannot be resolved through optimization
• Cross-reactivity that could produce clinically significant false positives
• Instability of the analyte under expected storage conditions
• Discrepancies between the assay and a reference method that exceed acceptable limits
• Cut-off values that do not achieve adequate sensitivity and specificity for the intended use

The bovine tuberculosis ELISA validation demonstrated the importance of escalation criteria by identifying that the ELISA detected tuberculous cattle unidentified by the tuberculin skin test. Of 43 animals that were ELISA positive 15 to 17 days after a negative tuberculin skin test, 36 were confirmed as infected with Mycobacterium bovis by histopathology and polymerase chain reaction. This finding illustrates that validation can reveal limitations in existing testing strategies and support improvements in diagnostic algorithms.

Safety and Biosafety Considerations

ELISA validation involves handling biological samples, reference standards, and potentially infectious materials. The World Health Organization Laboratory Biosafety Manual provides guidance on safe handling of biological materials in laboratory settings.

Follow these safety practices during validation:

• Treat all human samples as potentially infectious
• Use appropriate personal protective equipment including gloves and laboratory coats
• Follow your institution's biosafety guidelines for handling biological materials
• Dispose of samples and reagents according to applicable regulations
• Decontaminate work surfaces after handling samples
• Follow your institution's chemical safety guidelines for reagents such as substrates and stop solutions

The bovine tuberculosis ELISA validation involved testing serum from cattle, some of which were confirmed infected with Mycobacterium bovis. Such work requires appropriate biosafety containment and adherence to veterinary diagnostic laboratory safety protocols.

Limitations of ELISA Validation

ELISA validation has inherent limitations that should be acknowledged in the validation report. The allergen analysis review notes that all methods exhibit a relatively high level of uncertainty of measurement due to natural variation and production-related changes in the structures relevant to detection. No method provides absolute correct quantification.

Validation is specific to the conditions under which it was performed. Changes in reagent lots, equipment, operators, or sample types may require revalidation or at least verification that the assay continues to perform acceptably. The World Health Organization Laboratory Quality Management System Handbook emphasizes that validation is not a one-time event but an ongoing process.

ELISA results may not correlate perfectly with reference methods. The diphtheria antitoxin validation found that the correlation between ELISA results against diphtheria toxoid and the gold standard diphtheria toxin neutralization test values is poor when ELISA values are below 0.1 IU/mL. This limitation affects the accuracy of population immunity estimates when ELISA is used for measuring antibody levels.

Frequently Asked Questions

What is the difference between validation and verification of an ELISA?

Validation establishes that an assay performs reliably for its intended use through a documented series of experiments. Verification confirms that an already validated assay performs acceptably in a specific laboratory setting. Commercial kit users typically perform verification instead of full validation, confirming that the kit works as claimed in their laboratory with their equipment and operators. The World Health Organization Laboratory Quality Management System Handbook distinguishes between these activities and requires both to be documented.

How many replicates are needed for precision testing?

The number of replicates depends on the statistical confidence required and the variability of the assay. Published validation studies use varying numbers of replicates. The microcystin validation assessed intra-assay, inter-assay, and reproducibility variability with coefficients of variation below 11%, 15%, and 21% respectively. At minimum, test each concentration level in duplicate or triplicate within a run for repeatability assessment, and repeat the testing on at least three separate days for intermediate precision assessment.

What is the difference between limit of detection and limit of quantification?

The limit of detection is the lowest concentration that can be reliably distinguished from a blank sample. The limit of quantification is the lowest concentration that can be measured with acceptable accuracy and precision. The microcystin validation reported a limit of detection of 0.002 μg/L and a lower limit of quantification of 0.05 μg/L. Concentrations between the limit of detection and limit of quantification can be detected but not reliably quantified.

How do I choose between receiver operating characteristic analysis and other cut-off methods?

Receiver operating characteristic analysis is generally preferred when a well-characterized panel of known positive and negative samples is available. The SARS-CoV-2 antibody validation compared multiple methods and selected receiver operating characteristic analysis as the best method, achieving spike-directed sensitivity of 95.33% and specificity of 94.15%. When such a panel is unavailable, alternative methods such as mean plus standard deviations of negative samples may be used, but the limitations should be documented.

What should I do if my validation results fail to meet acceptance criteria?

Investigate the cause of the failure before making decisions about the assay. Common causes include matrix interference, operator error, reagent problems, or equipment malfunction. The aflatoxin kit validation identified a critical point of the method as incubation for 30 minutes at room temperature, illustrating that timing control can be essential. If the failure cannot be resolved through troubleshooting, escalate the issue to a laboratory supervisor or quality manager. Document all investigations and their outcomes.

How often should an ELISA be revalidated?

Revalidation is required when significant changes occur that could affect assay performance. These changes include new reagent lots, new equipment, new operators, changes in sample types, or modifications to the assay protocol. The World Health Organization Laboratory Quality Management System Handbook emphasizes that validation is an ongoing process. Some laboratories also perform periodic verification to confirm that the assay continues to perform acceptably over time.

Can I use validation data from the kit manufacturer instead of performing my own validation?

Manufacturer validation data provides useful background information but does not replace laboratory-specific verification. The World Health Organization Laboratory Quality Management System Handbook requires that all examination procedures be validated before use in a diagnostic laboratory. Commercial kits must be verified in your laboratory to confirm that the kit performs as expected with your equipment, operators, and sample types. The bovine tuberculosis ELISA validation reported high reproducibility through interlaboratory testing with a Pearson coefficient of 0.9648, demonstrating that assay performance can vary between laboratories.

What is dilutional parallelism and why does it matter?

Dilutional parallelism assesses whether high-concentration samples can be diluted into the working range without introducing bias. The progranulin assay validation reported dilution linearity ranging from 1:50 to 1:200. The microcystin validation recommended diluting samples to the working range when concentrations exceeded 5 μg/L. Without parallelism testing, results from diluted samples may not accurately reflect the true analyte concentration.

Related Diagnostic Guides

• DNA Quantification Using Picogreen Assay: Protocol and Sensitivity
• ELISA Assay Principle: How Enzyme-Linked Immunosorbent Assay Works
• How to Interpret a Bradford Assay Standard Curve: Linearity, R², and Outliers
• Spectrophotometer Calibration: Wavelength Accuracy and Absorbance Linearity Checks
• Multiplex Real-Time RT-PCR Detection of Canine Respiratory Pathogens Including Canine Distemper Virus, Bordetella bronchiseptica, and H3N8 Influenza: Analytical Sensitivity and Clinical Validation in Nasal Swabs

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Simplified validation of the ELISA kit determination of Microcystins in surface water.. Water science and technology : a journal of the International Association on Water Pollution Research, 2022.
• Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias.. Clinical chemistry and laboratory medicine, 2023.
• Important Considerations for ELISpot Validation.. Methods in molecular biology (Clifton, N.J.), 2024.
• [Allergen analysis].. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2016.
• Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.. Frontiers in immunology, 2023.
• Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis.. Hepatology communications, 2024.
• Evaluation and validation of a commercial ELISA versus the in vitro toxin neutralization assay for determination of diphtheria anti-toxin in human serum.. Journal of medical microbiology, 2023.
• Development and diagnostic validation of an ELISA based on an antigenic mixture for the detection of bovine tuberculosis.. Veterinary journal (London, England : 1997), 2020.
• Immunogenicity assessment for vidutolimod: a risk-driven approach for a simplified 1-tiered, singlicate anti-drug antibody testing strategy.. 2026.
• Advances in Point-of-Care Infectious Disease Diagnostics: Integration of Technologies, Validation, Artificial Intelligence, and Regulatory Oversight.. 2025.
• Blood-based biomarkers for Alzheimer's disease diagnosis: a joint position paper from the Italian Societies of Neurology (SIN) and of Clinical Biochemistry and Clinical Molecular Biology - Laboratory Medicine(SIBioC) and from the Autonomous Association affiliated with SIN for dementia (SINdem).. 2026.
• 25 years of applying the 3Rs principles in safety pharmacology: success stories and future perspectives.. 2026.
• Development and Characterization of Dual-Platform Lyophilized Plasma-Based Quality Control Materials for Hepatitis C Virus Antibody Testing. 2026.
• An In-House ELISA for Anti-Porcine Circovirus Type 2d (PCV2d) IgG: Analytical Validation and Serological Correlation. Vaccines, 2025.
• Development and field validation of an indirect ELISA for serosurveillance of Ornithodoros lahorensis exposure.. Veterinary Parasitology: Regional Studies and Reports, 2025.
• Validation Parameters for Quantitating Specific Proteins Using ELISA or LC-MS/MS: Survey Results. Food Analytical Methods, 2017.
• Validation of an ELISA method for determination of physical particle titre of AAV2-based vector preparations.. Pharmeuropa Bio & Scientific Notes, 2024.
• ELISA validation approach for the detection of anti-saccharomyces cerevisiae antibodies in patients treated with biopharmaceutical heberprot-P®. Journal of Analytical & Pharmaceutical Research, 2021.
• Validation of an ELISA test kit for the quantitative analyses of total Aflatoxins in spices marketed in Cameroon. Magna Scientia Advanced Research and Reviews, 2023.
• The comparision of the elisa method validation parameters by means of commercially available elisa kits for proinsulin quantification in human genetic ingeneering insulin substance. Russian Journal of Biopharmaceuticals, 2014.
• Operational validation of a commercial ELISA for Brucella ovis, Chile. Archivos De Medicina Veterinaria, 2007.
• Validation of Commercial ELISA kit for Non-Invasive Measurement of Cortisol Concentrations and the Evaluation of the Sampling Time of Blood and Fecal Sample in Aceh Cattle. E3s Web of Conferences, 2020.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.